BACKGROUND: Prior studies assessing the correlation of Gleason score (GS) at needle biopsy and corresponding radical prostatectomy (RP) predated the use of the modified Gleason scoring system and did not factor in tertiary grade patterns. OBJECTIVE: To assess the relation of biopsy and RP grade in the largest study to date. DESIGN, SETTING, AND PARTICIPANTS: A total of 7643 totally embedded RP and corresponding needle biopsies (2004-2010) were analyzed according to the updated Gleason system. INTERVENTIONS: All patients underwent prostate biopsy prior to RP. MEASUREMENTS: The relation of upgrading or downgrading to patient and cancer characteristics was compared using the chi-square test, Student t test, and multivariable logistic regression. RESULTS AND LIMITATIONS: A total of 36.3% of cases were upgraded from a needle biopsy GS 5-6 to a higher grade at RP (11.2% with GS 6 plus tertiary). Half of the cases had matching GS 3+4=7 at biopsy and RP with an approximately equal number of cases downgraded and upgraded at RP. With biopsy GS 4+3=7, RP GS was almost equally 3+4=7 and 4+3=7. Biopsy GS 8 led to an almost equal distribution between RP GS 4+3=7, 8, and 9-10. A total of 58% of the cases had matching GS 9-10 at biopsy and RP. In multivariable analysis, increasing age (p<0.0001), increasing serum prostate-specific antigen level (p<0.0001), decreasing RP weight (p<0.0001), and increasing maximum percentage cancer/core (p<0.0001) predicted the upgrade from biopsy GS 5-6 to higher at RP. Despite factoring in multiple variables including the number of positive cores and the maximum percentage of cancer per core, the concordance indexes were not sufficiently high to justify the use of nomograms for predicting upgrading and downgrading for the individual patient. CONCLUSIONS: Almost 20% of RP cases have tertiary patterns. A needle biopsy can sample a tertiary higher Gleason pattern in the RP, which is then not recorded in the standard GS reporting, resulting in an apparent overgrading on the needle biopsy.
BACKGROUND: Prior studies assessing the correlation of Gleason score (GS) at needle biopsy and corresponding radical prostatectomy (RP) predated the use of the modified Gleason scoring system and did not factor in tertiary grade patterns. OBJECTIVE: To assess the relation of biopsy and RP grade in the largest study to date. DESIGN, SETTING, AND PARTICIPANTS: A total of 7643 totally embedded RP and corresponding needle biopsies (2004-2010) were analyzed according to the updated Gleason system. INTERVENTIONS: All patients underwent prostate biopsy prior to RP. MEASUREMENTS: The relation of upgrading or downgrading to patient and cancer characteristics was compared using the chi-square test, Student t test, and multivariable logistic regression. RESULTS AND LIMITATIONS: A total of 36.3% of cases were upgraded from a needle biopsy GS 5-6 to a higher grade at RP (11.2% with GS 6 plus tertiary). Half of the cases had matching GS 3+4=7 at biopsy and RP with an approximately equal number of cases downgraded and upgraded at RP. With biopsy GS 4+3=7, RP GS was almost equally 3+4=7 and 4+3=7. Biopsy GS 8 led to an almost equal distribution between RP GS 4+3=7, 8, and 9-10. A total of 58% of the cases had matching GS 9-10 at biopsy and RP. In multivariable analysis, increasing age (p<0.0001), increasing serum prostate-specific antigen level (p<0.0001), decreasing RP weight (p<0.0001), and increasing maximum percentage cancer/core (p<0.0001) predicted the upgrade from biopsy GS 5-6 to higher at RP. Despite factoring in multiple variables including the number of positive cores and the maximum percentage of cancer per core, the concordance indexes were not sufficiently high to justify the use of nomograms for predicting upgrading and downgrading for the individual patient. CONCLUSIONS: Almost 20% of RP cases have tertiary patterns. A needle biopsy can sample a tertiary higher Gleason pattern in the RP, which is then not recorded in the standard GS reporting, resulting in an apparent overgrading on the needle biopsy.
Authors: Judson D Davies; Monty A Aghazadeh; Sharon Phillips; Shady Salem; Sam S Chang; Peter E Clark; Michael S Cookson; Rodney Davis; S Duke Herrell; David F Penson; Joseph A Smith; Daniel A Barocas Journal: J Urol Date: 2011-10-19 Impact factor: 7.450
Authors: D Colleselli; A E Pelzer; E Steiner; S Ongarello; G Schaefer; G Bartsch; C Schwentner Journal: Prostate Cancer Prostatic Dis Date: 2009-12-22 Impact factor: 5.554
Authors: Stephen J Freedland; Christopher J Kane; Christopher L Amling; William J Aronson; Martha K Terris; Joseph C Presti Journal: Urology Date: 2007-03 Impact factor: 2.649
Authors: L Spencer Krane; Mani Menon; Sanjeev A Kaul; Sameer A Siddiqui; Christel Wambi; James O Peabody; Piyush K Agarwal Journal: Urol Oncol Date: 2009-07-03 Impact factor: 3.498
Authors: Ayman S Moussa; Michael W Kattan; Ryan Berglund; Changhong Yu; Khaled Fareed; J Stephen Jones Journal: BJU Int Date: 2009-08-13 Impact factor: 5.588
Authors: Ryan S Turley; Martha K Terris; Christopher J Kane; William J Aronson; Joseph C Presti; Christopher L Amling; Stephen J Freedland Journal: BJU Int Date: 2008-09-03 Impact factor: 5.588
Authors: Lee Richstone; Fernando J Bianco; Hiral H Shah; Michael W Kattan; James A Eastham; Peter T Scardino; Douglas S Scherr Journal: BJU Int Date: 2008-03 Impact factor: 5.588
Authors: Trevor A Flood; Nicola Schieda; Daniel T Keefe; Rodney H Breau; Chris Morash; Kevin Hogan; Eric C Belanger; Kien T Mai; Susan J Robertson Journal: Virchows Arch Date: 2016-07-10 Impact factor: 4.064
Authors: Shekoofeh Azizi; Sharareh Bayat; Pingkun Yan; Amir Tahmasebi; Guy Nir; Jin Tae Kwak; Sheng Xu; Storey Wilson; Kenneth A Iczkowski; M Scott Lucia; Larry Goldenberg; Septimiu E Salcudean; Peter A Pinto; Bradford Wood; Purang Abolmaesumi; Parvin Mousavi Journal: Int J Comput Assist Radiol Surg Date: 2017-06-20 Impact factor: 2.924
Authors: Anup Vora; Tim Large; Jenny Aronica; Sherod Haynes; Andrew Harbin; Daniel Marchalik; Hanaa Nissim; John Lynch; Gaurav Bandi; Kevin McGeagh; Keith Kowalczyk; Reza Ghasemian; Krishnan Venkatesan; Mohan Verghese; Jonathan Hwang Journal: Int Urol Nephrol Date: 2013-07-18 Impact factor: 2.370
Authors: Shanshan Zhao; Milan S Geybels; Amy Leonardson; Rohina Rubicz; Suzanne Kolb; Qingxiang Yan; Brandy Klotzle; Marina Bibikova; Antonio Hurtado-Coll; Dean Troyer; Raymond Lance; Daniel W Lin; Jonathan L Wright; Elaine A Ostrander; Jian-Bing Fan; Ziding Feng; Janet L Stanford Journal: Clin Cancer Res Date: 2016-06-29 Impact factor: 12.531
Authors: Elmira Hassanzadeh; Daniel I Glazer; Ruth M Dunne; Fiona M Fennessy; Mukesh G Harisinghani; Clare M Tempany Journal: Abdom Radiol (NY) Date: 2017-01
Authors: Roderick C N van den Bergh; Peter C Albertsen; Chris H Bangma; Stephen J Freedland; Markus Graefen; Andrew Vickers; Henk G van der Poel Journal: Eur Urol Date: 2013-02-22 Impact factor: 20.096
Authors: Karim Chamie; Geoffrey A Sonn; David S Finley; Nelly Tan; Daniel J A Margolis; Steven S Raman; Shyam Natarajan; Jiaoti Huang; Robert E Reiter Journal: Urology Date: 2014-02 Impact factor: 2.649